Otsuka has a proud history of discovering, developing and delivering new medicines to patients in need. We have a number of approved products in Australia and New Zealand and new treatments that are progressing through clinical trials.

To view the Product Information (PI), Data Sheet and Consumer Medical Information (CMI) for each of our products, please click on the links below:

Approved products in Australia

For healthcare professionals
Abilify® (aripiprazole)
PI
ABILIFY MAINTENA® (aripiprazole (as monohydrate))*
PI
Abilify Asimtufii® (aripiprazole (as monohydrate))*
PI
Busulfex® (busulfan)
PI
Jinarc® (tolvaptan)
PI
REXULTI® (brexpiprazole)*
PI
Samsca® (tolvaptan)
PI
For consumers
Abilify® (aripiprazole)
CMI
ABILIFY MAINTENA® ((aripiprazole (as monohydrate)) )
CMI
Abilify Asimtufii® (aripiprazole (as monohydrate))*
CMI
Busulfex® (busulfan)
CMI
Jinarc® (tolvaptan)
CMI
REXULTI® (brexpiprazole)
CMI
Samsca® (tolvaptan)
CMI

Approved products in New Zealand

For healthcare professionals
Abilify® (aripiprazole)
Data Sheet
ABILIFY MAINTENA® (aripiprazole (as monohydrate))*
Data Sheet
Jinarc® (tolvaptan)
Data Sheet
For consumers
Abilify® (aripiprazole)
CMI
ABILIFY MAINTENA® ((aripiprazole (as monohydrate)) )
CMI
Jinarc® (tolvaptan)
CMI

*Abilify Maintena®, Rexulti® and Abilify Asimtufii® are sponsored by Lundbeck Australia and co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Ltd.

Otsuka Australia Pharmaceutical Pty Limited
Suite 2.03, Level 2,
9 Help Street,
Chatswood NSW 2067

Lundbeck Australia Pty Limited
Ground Floor
1 Innovation Road
North Ryde NSW 2113
Ph: +61 2 8669 1000

For further information about any of these products, please contact us.

Products: ABILIFY® (maintena), Abilify® (aripiprazole), Busulfex® (busulfan)Jinarc® (tolvaptan), Pletal® (cilostazol), Samsca® (tolvaptan), REXULTI® (brexpiprazole)